Donanemab resulted in 40 per cent less decline in the ability to perform activities of daily living, Eli Lilly said. Photo: Unsplash
Donanemab resulted in 40 per cent less decline in the ability to perform activities of daily living, Eli Lilly said. Photo: Unsplash
World 'on cusp of new treatments for Alzheimer's disease'
Donanemab is the second drug in the last year to excite dementia experts
